Navigation Links
Lotus Pharmaceuticals Announces Two Senior Management Appointments
Date:9/23/2010

Lotus Pharmaceuticals Announces Two Senior Management Appointments -- BEIJING, Sept. 23 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
OTC, SmallCap, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Personnel Announcements Click to view news release full screen  

Lotus Pharmaceuticals Announces Two Senior Management Appointments

 

BEIJING, Sept. 23 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that the Company has appointed Mr. Xing Shen as its Vice President of Corporate Development and Ms. Yan Zeng as its Chief Financial Officer. Ms. Zeng, who served as CFO of Lotus in 2009 and early 2010, will relieve Mr. Jeff Hon. Mr. Hon submitted his resignation to the Company's board of directors, effective September 22, citing personal reasons.

In his new role as Vice President of Corporate Development, Mr. Xing Shen will oversee the Company's strategic business development and internal investor relations functions. Prior to his tenure with Lotus, Mr. Shen worked as an equity analyst at RBC Capital Markets, covering companies in the biotech space. He holds an MBA and a PhD in molecular cancer biology, both from Duke University, as well as a Master of Science degree from Peking University and a Bachelor of Science degree from Wuhan University.

Ms. Yan Zeng is a certified public accountant (CPA) and served as the Company's Chief Financial Officer prior to Jeff Hon's appointment. She also has accounting experience with Liang Fang Pharmaceutical Ltd., a subsidiary of the Company. Prior to joining the Company, Ms. Zeng worked as a registered accountant and auditor with Beijing Topson Certified Public Accountants and as a financial manager for Beijing Unite Youbang Science and Technology Ltd. She holds a bachelor's degree in business from Beijing Information Science and Technology University.

"We are pleased to have Dr. Shen serve as our VP of Corporate Development and believe that his experience with the Company and background in both biotech and finance will prove to be a powerful combination that will benefit Lotus over the long run. We are also pleased to have Yan Zeng return as our CFO, despite Jeff Hon's unfortunate departure," said Dr. Zhongyi Liu, Lotus' Chairman and Chief Executive Officer. "By building a solid senior management team with significant industry experience, we are positioning ourselves to capture a greater share of the pharmaceutical market in China and sustain a high rate of growth while maintaining internal control."

About Lotus Pharmaceuticals, Inc.

Lotus Pharmaceuticals, Inc. is a fast-growing, profitable developer and producer of drugs and a licensed national seller of pharmaceutical items in the People's Republic of China (PRC). Lotus operates its business through its two controlled entities: Liang Fang Pharmaceutical, Ltd. and En Ze Jia Shi Pharmaceutical, Ltd. Lotus' current drug development is focused on the treatment of cerebro-cardiovascular diseases, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

Information Regarding Forward-Looking Statements

Except for historical information contained herein, the statements in this press release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause our actual results in future periods to differ materially from forecasted results. These risks and uncertainties include, among other things, product demand, market competition, and risks inherent in our operations. These and other risks are described in our filings with the U.S. Securities and Exchange Commission.

For more information, please contact: At the Company: Xing Shen, Ph.D. VP of Corporate Development Lotus Pharmaceuticals, Inc. Tel: +1-415-200-8482 Email: shen@lotuspharma.com Web: http://www.lotuspharma.com Investor Relations: Dave Gentry RedChip Companies, Inc. Tel: +1-800-733-2447 x104 Email: info@redchip.com Web: http://www.RedChip.com
'/>"/>

SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals Announces Engagement of RedChip Companies to Lead Public and Investor Relations Efforts
2. Lotus Pharmaceuticals Enter R-Bambuterol(R) Clinical Trial I
3. Lotus Pharmaceuticals Reports Strong Second Quarter 2010 Financial Results
4. Lotus Completed R-Bambuterols Pilot Scale Production for Clinical Trials
5. Lotus Pharmaceuticals Terminates SEDA
6. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
7. Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform
8. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
9. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
10. Lotus Pharmaceuticals to Exhibit at the 63rd PHARMCHINA
11. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... Pa. , Dec. 9, 2016 Department ... announced temporary regulations for medical marijuana dispensaries under Act ... Pennsylvania Bulletin , and are now available online ... is needed in the plan for operation; process for ... dispensary; as well as where the dispensary facilities can ...
(Date:12/8/2016)... Calif. , Dec. 8, 2016 IRIDEX Corporation ... to offer newly issued shares of common stock, $0.01 par ... to an underwritten public offering.  The final terms of the ... time of pricing, and there can be no assurance as ... IRIDEX expects to use the net proceeds it will ...
(Date:12/8/2016)... NEW YORK , Dec. 8, 2016 ... ... such as reducing loss of blood during surgeries, lowering the ... surgeries, and decreasing risks of SSIs. The patient warming systems ... and intravascular warming systems.These benefits in turn reduce the stay ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) aired ... of 2016. The program was made possible by a Pennsylvania Department of Health ... and Human Services Administration. The broadcast, Use Your Head: Properly Managing Sport ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... has been recognized for adherence to the highest standards of trauma, maternity, ... organizations, announced the center's president and CEO, Dr. Daniel Messina. , Among the ...
(Date:12/8/2016)... San Francisco, California (PRWEB) , ... December 08, 2016 , ... ... health coaches, has raised an $18M Series B led by Canvas Ventures . ... use the capital to scale its mobile platform to serve more consumers who are ...
Breaking Medicine News(10 mins):